<DOC>
	<DOCNO>NCT02779101</DOCNO>
	<brief_summary>In summary , high medical need patient suffer recurrent/progressive PCNSL . Targeting PD-1 pathway may represent promise novel approach treatment patient .</brief_summary>
	<brief_title>Study Pembrolizumab Recurrent Primary Central Nervous System Lymphoma ( PCNSL )</brief_title>
	<detailed_description>The objective study : PRIMARY OBJECTIVES - To evaluate Overall Response Rate ( CR/PR ) patient treat pembrolizumab relapse PCNSL MTX-based first-line therapy - To evaluate safety pembrolizumab subject diagnose recurrent PCNSL SECONDARY OBJECTIVES - To describe Best Overall Response category ( CR , PR , SD , PD ) patient treat pembrolizumab relapse PCNSL MTX-based first-line therapy - To describe individual duration response time - To assess progression-free survival patient population - To assess overall survival patient population EXPLORATORY OBJECTIVES - To assess PD-L1 predictive marker response pembrolizumab</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Minimum 18 year age day sign informed consent . Histologically confirm diagnosis PCNSL ( DLBCL ) initial diagnosis The patient Karnofsky performance status least 50 % . Documented progression recurrence cranial MRI prior MTXbased firstline therapy ( without prior radiotherapy ) Measurable disease cranial MRI ( lesion size &gt; 10x10mm ) Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment except maximum dose 4 mg/day dexamethasone equivalent dose corticosteroid control brain edema , stable decrease least 1 week prior inclusion . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Female patient childbearing potential negative urine serum pregnancy test within 24 hour first pembrolizumab infusion . lf urine test positive confirm negative , serum pregnancy test require . The serum pregnancy test must negative patient eligible . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . The patient life expectancy least 3 month . The patient Karnofsky performance status least 50 % . The patient demonstrate adequate organ function Patient able undergo GadoliniumMRI Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . Concurrent administration antitumor therapy except steroid Known additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergone potentially curative therapy situ cervical cancer . Has active infection require systemic therapy . Known history active TB ( Bacillus Tuberculosis ) Known history , evidence active , noninfectious pneumonitis . Has receive live vaccine within 30 day plan start study therapy . Note : Seasonal influenza vaccine injection generally inactivate flu vaccine allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine , allow . Drug abuse extensive use alcohol . Active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Positive human immunodeficiency virus ( HIV ) test know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Known psychiatric substance abuse disorder would interfere cooperation requirement trial . History allergy study drug component history severe hypersensitivity reaction monoclonal antibody . Prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 . Has recover ( i.e.Grade 1 baseline ) adverse event due agent administer 4 week earlier . Known hypersensitivity pembrolizumab excipients . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . History current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Central nervous system lymphoma</keyword>
	<keyword>Pembrolizumab</keyword>
</DOC>